BR112012015084A2 - composição farmacêutica de liberação lenta de iloperidone - Google Patents
composição farmacêutica de liberação lenta de iloperidoneInfo
- Publication number
- BR112012015084A2 BR112012015084A2 BR112012015084A BR112012015084A BR112012015084A2 BR 112012015084 A2 BR112012015084 A2 BR 112012015084A2 BR 112012015084 A BR112012015084 A BR 112012015084A BR 112012015084 A BR112012015084 A BR 112012015084A BR 112012015084 A2 BR112012015084 A2 BR 112012015084A2
- Authority
- BR
- Brazil
- Prior art keywords
- slow release
- iloperidone
- pharmaceutical composition
- release pharmaceutical
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Abstract
composição farmacêutica de liberação lenta de iloperidone. a presente invenção refere-se a uma composição farmacêutica de libertação lenta compreendendo iloperidone ou dos seus metabolitos activos e um agente de libertação lenta é descrito. também divulgado é de libertação lenta composição farmacêutica compreendendo iloperidone ou dos seus metabolitos activos, em que a composição de libertação lenta é uma combinação de uma composição de libertação controlada e uma composição de libertação imediata.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN1473KO2009 | 2009-12-23 | ||
PCT/IB2010/003346 WO2011077239A2 (en) | 2009-12-23 | 2010-12-23 | Slow release pharmaceutical compositions of iloperidone |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112012015084A2 true BR112012015084A2 (pt) | 2017-03-07 |
Family
ID=43896764
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112012015084A BR112012015084A2 (pt) | 2009-12-23 | 2010-12-23 | composição farmacêutica de liberação lenta de iloperidone |
Country Status (5)
Country | Link |
---|---|
US (1) | US20130004545A1 (pt) |
EP (1) | EP2515863A2 (pt) |
BR (1) | BR112012015084A2 (pt) |
MX (1) | MX2012007365A (pt) |
WO (1) | WO2011077239A2 (pt) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2993780B1 (fr) | 2012-07-26 | 2015-02-13 | Assist Publ Hopitaux De Paris | Methode de traitement de la sclerose en plaque |
ITMI20121263A1 (it) * | 2012-07-19 | 2014-01-20 | Recordati Ind Chimica E Farma Ceutica S P A | Forma farmaceutica multistrato |
US9789092B2 (en) | 2013-04-29 | 2017-10-17 | Assistance Publique—Hopitaux de Paris | Biotin for use in treating X-linked adrenoleukodystrophy |
EP3072513A1 (en) | 2015-03-26 | 2016-09-28 | Medday | Biotin for treating Amyotrophic lateral sclerosis |
WO2017086835A1 (ru) * | 2015-11-17 | 2017-05-26 | Общество С Ограниченной Ответственностью "Валента-Интеллект" | Фармацевтическая композиция, обладающая терапевтическим эффектом в отношении демиелинизирующих заболеваний (варианты) |
RU2638803C2 (ru) * | 2016-06-09 | 2017-12-15 | Общество С Ограниченной Ответственностью "Валента-Интеллект" | Таблетки биотина с замедленным высвобождением и способ их получения |
EP3275439A1 (en) | 2016-07-29 | 2018-01-31 | Medday Pharmaceuticals | Method for treating hepatic encephalopathy |
EP3344011A1 (fr) * | 2016-12-28 | 2018-07-04 | Stephane Bochenek | Generateur de lumiere pour le blanchiment des dents |
EP3459534A1 (en) | 2017-09-22 | 2019-03-27 | Institut Regional du Cancer de Montpellier | Method for treating or preventing radiotherapy induced breast fibrosis |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4783337A (en) | 1983-05-11 | 1988-11-08 | Alza Corporation | Osmotic system comprising plurality of members for dispensing drug |
US4765989A (en) | 1983-05-11 | 1988-08-23 | Alza Corporation | Osmotic device for administering certain drugs |
US4612008A (en) | 1983-05-11 | 1986-09-16 | Alza Corporation | Osmotic device with dual thermodynamic activity |
US5364866A (en) | 1989-05-19 | 1994-11-15 | Hoechst-Roussel Pharmaceuticals, Inc. | Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics |
SK6412002A3 (en) | 1999-11-11 | 2002-09-10 | Pharmacia Ab | Pharmaceutical formulation containing tolterodine and its use |
JP2005504783A (ja) | 2001-08-31 | 2005-02-17 | ノバルティス アクチエンゲゼルシャフト | イロペリドン代謝産物の光学異性体 |
JP5067998B2 (ja) * | 2001-10-30 | 2012-11-07 | ノバルティス アーゲー | イロペリドンおよび星形ポリマーのデポー製剤 |
GB0216416D0 (en) * | 2002-07-15 | 2002-08-21 | Novartis Ag | Organic compounds |
US7704527B2 (en) * | 2002-10-25 | 2010-04-27 | Collegium Pharmaceutical, Inc. | Modified release compositions of milnacipran |
EP1841414A1 (en) * | 2003-12-31 | 2007-10-10 | Alpharma, Inc. | Rosiglitazone and metformin formulations |
JP5095615B2 (ja) * | 2005-06-27 | 2012-12-12 | バリアント・インターナショナル・(バルバドス)・ソサイアティーズ・ウィズ・リストリクティッド・ライアビリティ | ブプロピオン塩の放出調整製剤 |
US20090306137A1 (en) * | 2006-05-22 | 2009-12-10 | Wolfgang Curt D | Treatment for depressive disorders |
WO2007137224A2 (en) * | 2006-05-22 | 2007-11-29 | Vanda Pharmaceuticals, Inc. | Method of treatment |
CA2661683C (en) * | 2006-08-31 | 2015-11-24 | Eurand, Inc | Drug delivery systems comprising solid solutions of weakly basic drugs |
PL2222300T3 (pl) | 2007-12-13 | 2015-02-27 | Vanda Pharmaceuticals Inc | Sposób i skład preparatu do leczenia chorób z udziałem receptorów serotoniny |
MX2010006520A (es) | 2007-12-13 | 2010-11-30 | Vanda Pharmaceuticals Inc | Metodo y composicion para el tratamiento de una condicion mediada por alfa-adrenoceptor. |
-
2010
- 2010-12-23 EP EP10812902.4A patent/EP2515863A2/en not_active Withdrawn
- 2010-12-23 BR BR112012015084A patent/BR112012015084A2/pt not_active IP Right Cessation
- 2010-12-23 WO PCT/IB2010/003346 patent/WO2011077239A2/en active Application Filing
- 2010-12-23 US US13/518,102 patent/US20130004545A1/en not_active Abandoned
- 2010-12-23 MX MX2012007365A patent/MX2012007365A/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO2011077239A3 (en) | 2012-04-12 |
MX2012007365A (es) | 2012-08-15 |
WO2011077239A2 (en) | 2011-06-30 |
US20130004545A1 (en) | 2013-01-03 |
EP2515863A2 (en) | 2012-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112012015084A2 (pt) | composição farmacêutica de liberação lenta de iloperidone | |
UA118177C2 (uk) | Композиція для лікування гіперліпідемії, яка містить похідну оксинтомодуліну | |
CL2010001428A1 (es) | Compuestos derivados de amidas y tioamidas heteroaromaticas; agente que contiene al menos uno de dichos compuestos; procedimiento para combatir parasitos; y uso de dichos compuestos. | |
BR112013030599A2 (pt) | núcleo absorvente para artigos absorventes descartáveis | |
BR112015021352A2 (pt) | composições antimicrobianas | |
BRPI1012170A2 (pt) | formulação e/ou sublingual e método para reduzir a quantidade de composto ativo usado para alcançar um efeito em um paciente em comparação com um composto típico que é ingerido. | |
BR112012019529A2 (pt) | inibidores de d-nitrosoglutationa redutase | |
BR112012008823B8 (pt) | compostos que modulam receptor de androgênio, composição farmacêutica compreendendo os ditos compostos e usos dos mesmos para a prevenção ou tratamento de distúrbios dependentes de receptores de androgênio | |
CL2013000304A1 (es) | Compuestos derivados de 2-arilamino-bencimidazoles inhibidores de prostaglandina e2 (mpges-1); composicion farmaceutica que los comprende; compuestos intermediarios; uso en el tratamiento de enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor. | |
BR112012006692A2 (pt) | composição farmacêutica compreendendo ácido graxo de omega-3 e um derivado de hidróxi de uma estatina e métodos de uso das mesmas | |
GT200600194A (es) | Composiciones farmaceuticas conteniendo imatinib y un componente de liberacion prolongada | |
EA201071378A1 (ru) | Дронедарон для предотвращения постоянной фибрилляции предсердий | |
CL2012003226A1 (es) | Compuestos derivados de 5-fluoro-1h-pirazolopiridina ; procedimiento de preparacion de estos; composicion framaceutica que los comprende; y su uso en el tratamiento de enfermedades cardiovasculares, sexuales y metabolicas. | |
UY31080A1 (es) | Derivados de pirazol sustituidos con heteroarilo utiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogénesis | |
CL2007003587A1 (es) | Compuestos derivados de pirimidinas sustituidas; composicion farmaceutica que comprende a dichos compuestos y otro agente activo; y su uso para tratar o prevenir la infeccion de la hepatitis c. | |
BR112015026021A2 (pt) | terapia de combinação compreendendo um inibidor de tor quinase e n-(3-(5-flúor-2-(4-(2-met-oxietoxi)fenilamino)pirimidin-4-ilamino)fenil)acrilamida para o tratamento de câncer | |
BR112016001446A8 (pt) | composições terapêuticas, produto de combinação, uso in vitro de flecainida e flecainida | |
BR112012032087A2 (pt) | composto, medicamento, e, uso de um composto | |
BR112014020113A8 (pt) | Composições farmacêuticas e método para diminuir a frequência de micção | |
EA201101116A1 (ru) | Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина | |
BR112012004851B8 (pt) | uso de um derivado de tiazol | |
BR112012019351A2 (pt) | composição de combinação, que inclui como ingredientes ativos l-carnitina ou propionil l-carnitina, para a prevenção ou tratamento de insuficiência venosa crônica. | |
EA201101118A1 (ru) | Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина | |
BR112012027794A2 (pt) | tablete entérico | |
UY33530A (es) | Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A E 6A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |